News

Obstructive sleep apnea (OSA) is a common breathing disorder which affects 15 to 20 million people in the US alone. The condition is characterized by brief interruptions in

Bayer is hoping that the new long-acting product will change the existing treatment structure for the disease, because it may result weekly, or even less frequent, injections. Currently,

Conforma plans to market Sumitomo’s amrubicin in North America and Europe, with phase II trials scheduled for early 2006. Amrubicin was developed as a treatment for lung cancer,

The University plans to conduct basic, translational and clinical studies using Panzem NCD with a range of chemotherapeutic agents to determine the effect of Panzem, or 2ME2, on

The program consisted of two randomized, placebo-controlled clinical studies that were carried out in moderately depressed patients. One study, which was conducted in 248 depressed patients, demonstrated that

The company said the phase III segment is a randomized study that will compare 200mg daily of KRX-101 versus placebo in 1,000 patients with persistent microalbuminuria. The phase

The patent, which is entitled “AB42 Lowering Agents”, was licensed to Myriad from Rochester, Minnesota-based Mayo Clinic. Amyloid beta 42 is a neurotoxic peptide, which Myriad claims is

The results indicate that treatment with Actos lowered triglycerides, increased HDL-C or “good” cholesterol, and improved LDL-C or “bad” cholesterol particle concentration and particle size. Diabetic dyslipidemia is

The randomized single-dose study was designed to evaluate the pharmacokinetics of sumatriptan, a drug used to treat migraines, at three injection sites in 24 healthy adult male and